Rick Maffei, Author at Oncology Nurse Advisor Fri, 01 Dec 2023 15:05:43 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png Rick Maffei, Author at Oncology Nurse Advisor 32 32 Advancements in CLDN18.2 Targeted Therapy for the Management of Gastric Cancers https://www.oncologynurseadvisor.com/clinicianpov/gastric-cancer-cldn18-2-unresectable-diffuse-metastatic-monoclonal-antibody-chemotherapy/ Fri, 01 Dec 2023 15:05:43 +0000 ]]> ONA Summit Highlights Collaboration, How Oncology Nurses Thrive Under Pressure https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/ona-summit-2023/2023-ona-summit-oncology-nurses-managing-treatment-survivorship/ Wed, 15 Mar 2023 14:02:33 +0000 2023 ONA Summit]]> ONA Summit 2023 Native Newsletter Ad https://www.oncologynurseadvisor.com/?hm-html=ona-oncology-nurses-in-all-roles-ona-summit-01-2023 Wed, 04 Jan 2023 21:42:58 +0000 https://www.oncologynurseadvisor.com/?post_type=hm-html&p=104164 Future Implications of Targeting GPRC5D in Multiple Myeloma https://www.oncologynurseadvisor.com/clinicianpov/karen-luow-future-implications-targeting-gprc5d-multiple-myeloma-treatment/ Wed, 14 Dec 2022 16:12:03 +0000 ]]> Patient Education and Counseling in HER2-Positive Breast Cancer https://www.oncologynurseadvisor.com/thediscussionroom/counseling-patients-with-her2-positive-breast-cancers/ Thu, 15 Sep 2022 14:04:37 +0000 ]]> Ovarian Cancer Research From the 2022 ASCO® Annual Meeting: Treatment, Clinician Engagement, and the Future of Early Detection https://www.oncologynurseadvisor.com/meetinginsights/ovarian-cancer-research-from-the-2022-asco-annual-meeting-treatment-clinician-engagement-and-the-future-of-early-detection/ Tue, 28 Jun 2022 17:17:59 +0000 ]]> ONA – Breast Cancer 04.2022 https://www.oncologynurseadvisor.com/?hm-html=ona-breast-cancer-04-2022 Mon, 04 Apr 2022 19:52:26 +0000 https://www.oncologynurseadvisor.com/?post_type=hm-html&p=98138 ONA – MPN 04.2022 https://www.oncologynurseadvisor.com/?hm-html=ona-mpn-04-2022 Mon, 04 Apr 2022 19:51:08 +0000 https://www.oncologynurseadvisor.com/?post_type=hm-html&p=98137 Steroid-Refractory Chronic GVHD: Update on Treatment Options https://www.oncologynurseadvisor.com/howtotreat/ibrutinib-steroid-refractory-chronic-gvhd-graft-host-disease-update/ Tue, 29 Mar 2022 15:49:02 +0000 ]]> Practice-Changing Research in Myeloma: Expert Insights From ASH 2021 https://www.oncologynurseadvisor.com/meetinginsights/samir-hadidi-research-practicing-research-myeloma-expert-insight-ash-2021/ Wed, 12 Jan 2022 18:49:08 +0000 Samer A. Al Hadidi, MD, MS (CRDSA), FACP, is a hematologist/oncologist at the Myeloma Center at the Winthrop P. Rockefeller Cancer Institute of the University of Arkansas for Medical Sciences (UAMS) in Little Rock. Dr Al Hadidi is also an assistant professor in the UAMS College of Medicine’s Department of Hematology and Oncology. He shared his insight and key takeaways based on MM research presented at ASH 2021.]]>